IL147026A0 - Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence - Google Patents

Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence

Info

Publication number
IL147026A0
IL147026A0 IL14702600A IL14702600A IL147026A0 IL 147026 A0 IL147026 A0 IL 147026A0 IL 14702600 A IL14702600 A IL 14702600A IL 14702600 A IL14702600 A IL 14702600A IL 147026 A0 IL147026 A0 IL 147026A0
Authority
IL
Israel
Prior art keywords
transcripting
compositions
preventing
formation
plasmid sequence
Prior art date
Application number
IL14702600A
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of IL147026A0 publication Critical patent/IL147026A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
IL14702600A 1999-07-09 2000-06-27 Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence IL147026A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14305999P 1999-07-09 1999-07-09
PCT/US2000/017670 WO2001004313A1 (en) 1999-07-09 2000-06-27 Methods and compositions for preventing the formation of aberrant rna during transcription of a plasmid sequence

Publications (1)

Publication Number Publication Date
IL147026A0 true IL147026A0 (en) 2002-08-14

Family

ID=22502421

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14702600A IL147026A0 (en) 1999-07-09 2000-06-27 Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence

Country Status (10)

Country Link
EP (1) EP1194556A1 (en)
JP (1) JP2003504061A (en)
KR (1) KR20020030780A (en)
CN (1) CN1360631A (en)
AU (1) AU783681B2 (en)
BR (1) BR0012325A (en)
CA (1) CA2378653A1 (en)
IL (1) IL147026A0 (en)
MX (1) MXPA01013462A (en)
WO (1) WO2001004313A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP1555317B1 (en) 1998-03-20 2011-09-28 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs comprising the same
CA2361201A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US7601494B2 (en) 1999-03-17 2009-10-13 The University Of North Carolina At Chapel Hill Method of screening candidate compounds for susceptibility to biliary excretion
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20110097709A1 (en) * 2000-03-13 2011-04-28 Kidd Geoffrey L Method for modifying a nucleic acid
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
US6630589B1 (en) 2001-03-26 2003-10-07 Message Pharmaceuticals Identification of compounds for the treatment or prevention of proliferative diseases
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1800697B1 (en) 2001-06-05 2010-04-14 CureVac GmbH Stabilised mRNA with increased G/C-content for use in gene therapy
US7897382B2 (en) 2001-10-22 2011-03-01 Alnylam Pharmaceuticals, Inc. Transfection kinetics and structural promoters
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US20040180438A1 (en) 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
DE10229872A1 (en) 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
EP1623009A4 (en) * 2003-04-22 2008-02-13 Nucleonics Inc Transfection kinetics and structural promoters
AU2005212433B2 (en) 2003-05-23 2010-12-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sINA)
US20060019914A1 (en) 2004-02-11 2006-01-26 University Of Tennessee Research Foundation Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP2514758B2 (en) 2004-03-15 2021-06-23 City of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
EP1747022A4 (en) 2004-04-23 2010-03-31 Univ Columbia INHIBITION OF HAIRLESS PROTEIN mRNA
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20100132058A1 (en) 2004-07-23 2010-05-27 Diatchenko Luda B Methods and materials for determining pain sensitivity and predicting and treating related disorders
WO2007011702A2 (en) 2005-07-15 2007-01-25 The University Of North Carolina At Chapel Hill Use of egfr inhibitors to prevent or treat obesity
WO2007039454A1 (en) 2005-09-20 2007-04-12 Basf Plant Science Gmbh Methods for controlling gene expression using ta-siran
WO2008092153A2 (en) 2007-01-26 2008-07-31 University Of Louisville Research Foundation, Inc. Modification of exosomal components for use as a vaccine
BRPI0809130A2 (en) 2007-03-21 2014-08-26 Brookhaven Science Ass Llc HAIRPIN-ANTISENSE COMBINED COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION
EP3406720A1 (en) 2009-12-18 2018-11-28 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
CA2789125A1 (en) 2010-02-10 2011-08-18 Novartis Ag Methods and compounds for muscle growth
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9260471B2 (en) 2010-10-29 2016-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SG10201602654SA (en) 2011-10-03 2016-05-30 Moderna Therapeutics Inc Modified nucleosides,nucleotides,and nucleic acids,and uses thereof
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US10023862B2 (en) 2012-01-09 2018-07-17 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat beta-catenin-related diseases
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243950A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
PT2922554T (en) 2012-11-26 2022-06-28 Modernatx Inc Terminally modified rna
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
ES2806575T3 (en) 2013-11-01 2021-02-18 Curevac Ag Modified RNA with decreased immunostimulatory properties
EP3423568A4 (en) 2016-03-04 2019-11-13 University Of Louisville Research Foundation, Inc. Methods and compositions for ex vivo expansion of very small embryonic-like stem cells (vsels)
WO2020236597A1 (en) * 2019-05-17 2020-11-26 Massachusetts Institute Of Technology Engineered post-poly a signal rna and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587300A (en) * 1994-04-26 1996-12-24 Wisconsin Ulumni Research Foundation Method to increase regulatory molecule production
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US6022863A (en) * 1996-05-21 2000-02-08 Yale University Regulation of gene expression
WO1999010509A1 (en) * 1997-08-22 1999-03-04 The Government Of The United States Of America, Represented By The Secretary Of Health And Human Services, National Institutes Of Health Polynucleotide inhibition of rna destabilization and sequestration
US20030083272A1 (en) * 1997-09-19 2003-05-01 Lahive & Cockfield, Llp Sense mrna therapy

Also Published As

Publication number Publication date
JP2003504061A (en) 2003-02-04
MXPA01013462A (en) 2002-07-02
CN1360631A (en) 2002-07-24
BR0012325A (en) 2002-05-21
KR20020030780A (en) 2002-04-25
CA2378653A1 (en) 2001-01-18
EP1194556A1 (en) 2002-04-10
WO2001004313A1 (en) 2001-01-18
AU783681B2 (en) 2005-11-24
AU5893700A (en) 2001-01-30

Similar Documents

Publication Publication Date Title
IL147026A0 (en) Method and compositions for preventing the formation of aberrant rna during transcripting of a plasmid sequence
HUP0201188A2 (en) Hemisynthetic method and new compounds
IL146530A0 (en) Method of inhibiting neurotrophin-receptor binding
IL146529A0 (en) Method of inhibiting neurotrophin-receptor binding
AU2001283516A1 (en) Machine leveler and method
HUP0202537A3 (en) A vaccine composition and method of using the same
EG23819A (en) Method for preparing of l-phenylephrine-hydrochloride
HUP0101094A3 (en) Process for preparing a protected 4-aminomethyl-pyrrolidin-3-one and intermediates
IL145065A0 (en) Method for inhibiting angiogenesis
PL344390A1 (en) Method of obtaining derivatives of 1,4-dihydropyridine
IL148813A0 (en) Method for administering a phosphodiesterase 4 inhibitor
GB2353974B (en) Method of printing
IL145677A0 (en) Pcr-based cloning method
AU2001252686A1 (en) Cumulative point notifying method
EP1223962A4 (en) Method and compositions for inhibiting adhesion formation
AU2007901A (en) Method of delivering a benefit agent
ZA200106445B (en) Liposome composition and method for administration of a radiosensitizer.
GB9924752D0 (en) Method of construction
IL138998A0 (en) Improved method for preparing pharmaceutically valuable norbenzomorphane derivatives
GB2365910A8 (en) A method of engaging plant-on dividing bars
PL332676A1 (en) Method of obtaining benzidamine hydrochloride
PL336550A1 (en) Method of decoposing 2-chloroethenylchloroarsazine
SI1156999T1 (en) Method for the preparation of a chiral-beta-amino ester
GB9916959D0 (en) Method of printing
GB9916941D0 (en) Method of printing